Treace Medical Concepts (TMCI) EBIAT (2020 - 2025)
Treace Medical Concepts (TMCI) has disclosed EBIAT for 6 consecutive years, with -$9.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 1775.05% year-over-year to -$9.4 million, compared with a TTM value of -$59.0 million through Dec 2025, down 5.85%, and an annual FY2025 reading of -$59.0 million, down 5.85% over the prior year.
- EBIAT was -$9.4 million for Q4 2025 at Treace Medical Concepts, up from -$16.3 million in the prior quarter.
- Across five years, EBIAT topped out at -$501000.0 in Q4 2024 and bottomed at -$21.2 million in Q2 2024.
- Average EBIAT over 5 years is -$11.4 million, with a median of -$12.2 million recorded in 2022.
- The sharpest move saw EBIAT soared 92.02% in 2024, then tumbled 1775.05% in 2025.
- Year by year, EBIAT stood at -$6.6 million in 2021, then skyrocketed by 33.34% to -$4.4 million in 2022, then plummeted by 42.36% to -$6.3 million in 2023, then skyrocketed by 92.02% to -$501000.0 in 2024, then crashed by 1775.05% to -$9.4 million in 2025.
- Business Quant data shows EBIAT for TMCI at -$9.4 million in Q4 2025, -$16.3 million in Q3 2025, and -$17.4 million in Q2 2025.